The goal of DECIDE is to reduce disease and death from alcohol-related and non-alcoholic fatty liver diseases by:
•Development and validation of novel biomarkers of hepatic inflammation.
•Easy, operational decision aids for case-finding in primary care.
•Biomarkers for prognostication and monitoring longitudinal changes in liver fibrosis.
•Validated, publicly scalable instruments using narrative medicine to reduce stigma towards liver disease, alcohol and obesity.